Rating Change
HC Wainwright & Co. reiterated its Buy rating on Neurogene Inc. (NASDAQ:NGNE) on November 10, 2026.
reiterateNASDAQ:NGNE
HC Wainwright & Co. Reiterates Buy Rating on Neurogene Inc. (NGNE)
HC Wainwright & Co. reiterated its Buy rating on Neurogene Inc.
At publication ·
What changed
Neurogene Inc. (NASDAQ:NGNE) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Buy to Buy
- Price at event
- $26.07
- Market capitalization
- $329.3M
At a glance
Key takeaways
- HC Wainwright & Co. reiterated a Buy rating on Neurogene Inc. (NGNE) on November 10, 2026, with the stock trading at $26.07 and a market cap of $329.3 million.
- Among the 10 most recent analyst ratings, all 10 are Buy ratings with zero Hold or Sell recommendations, indicating strong consensus support.
- Analyst ratings are one input among many for investment decisions and historical studies show consensus recommendations have mixed predictive power on their own.
Market Context
Neurogene Inc. operates in the Healthcare sector. The stock currently trades at $26.07 with a market capitalization of $329.3M.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Neurogene Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Neurogene Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 10, 2026 | HC Wainwright & Co. | Buy | N/A |
| Oct 28, 2026 | HC Wainwright & Co. | Buy | N/A |
| Oct 08, 2026 | JP Morgan | Overweight | N/A |
| Aug 12, 2026 | Canaccord Genuity | Buy | N/A |
| Aug 12, 2026 | Guggenheim | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View NGNE Stock Page
Frequently Asked Questions
What does the Buy rating mean for NGNE?
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Neurogene Inc. (NASDAQ:NGNE). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the NGNE forecast page.
Loading related coverage…